Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
10 min read
Desmosterolosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
Explore the 2026 Desmosterolosis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Lathosterolosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
Explore the 2026 Lathosterolosis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Chylomicron retention disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Chylomicron retention disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Hypobetalipoproteinemia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Hypobetalipoproteinemia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Bile acid malabsorption Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Bile acid malabsorption strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Alagille syndrome cholestasis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Alagille syndrome cholestasis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Congenital bile acid synthesis defect Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Congenital bile acid synthesis defect strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Latest Hotspot
10 min read
Congenital disorder of glycosylation type 1a Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Congenital disorder of glycosylation type 1a strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Latest Hotspot
10 min read
Glutaric aciduria type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Glutaric aciduria type 2 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
L-2-hydroxyglutaric aciduria Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 L-2-hydroxyglutaric aciduria strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Ethylmalonic encephalopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Ethylmalonic encephalopathy strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Malonic aciduria Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
Explore the 2026 Malonic aciduria indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.